{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T02:57:29Z","timestamp":1792033049465,"version":"4.4.0"},"reference-count":26,"publisher":"American Academy of Pediatrics (AAP)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,9,1]]},"abstract":"<jats:p>The only indications for which a fluoroquinolone (ie, ciprofloxacin) is licensed by the US Food and Drug Administration for use in patients younger than 18 years are complicated urinary tract infections, pyelonephritis, and postexposure treatment for inhalation anthrax. Nonetheless, approximately 520 000 prescriptions for fluoroquinolones were written in the United States for patients younger than 18 years in 2002; 13 800 were written for infants and children 2 to 6 years of age, and 2750 were written for infants younger than 2 years. Clinical trials of fluoroquinolones in pediatric patients with various diagnoses have been published and are reviewed. Fluoroquinolones cause arthrotoxicity in juvenile animals and have been associated with reversible musculoskeletal events in both children and adults. Other adverse events associated with fluoroquinolones include central nervous system disorders, photosensitivity, disorders of glucose homeostasis, prolongation of QT interval with rare cases of torsade de pointes (often lethal ventricular arrhythmia in patients with long QT syndrome), hepatic dysfunction, and rashes. The increased use of fluoroquinolones in adults has resulted in increased bacterial resistance to this class of antibacterial agents. This report provides specific guidelines for the systemic use of fluoroquinolones in children. Fluoroquinolone use should be restricted to situations in which there is no safe and effective alternative to treat an infection caused by multidrug-resistant bacteria or to provide oral therapy when parenteral therapy is not feasible and no other effective oral agent is available.<\/jats:p>","DOI":"10.1542\/peds.2006-1722","type":"journal-article","created":{"date-parts":[[2006,9,1]],"date-time":"2006-09-01T21:17:38Z","timestamp":1157145458000},"page":"1287-1292","source":"Crossref","is-referenced-by-count":111,"title":["The Use of Systemic Fluoroquinolones"],"prefix":"10.1542","volume":"118","author":[{"name":"Committee on Infectious Diseases","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2006,9,1]]},"reference":[{"key":"2021120822583819900_R1","doi-asserted-by":"crossref","unstructured":"Schaad UB, Abdus Salam M, Aujard Y, et al. Use of fluoroquinolones in pediatrics: consensus report of an International Society of Chemotherapy commission. Pediatr Infect Dis J.\u20081995;14:1\u20139","DOI":"10.1097\/00006454-199501000-00001"},{"key":"2021120822583819900_R2","unstructured":"Shalit I, Stutman HR, Marks MI, Chartrand SA, Hilman BC. Randomized study of two dosage regimens of ciprofloxacin for treating chronic bronchopulmonary infection in patients with cystic fibrosis. Am J Med.\u20081987;82(suppl 4A):189\u2013195"},{"key":"2021120822583819900_R3","doi-asserted-by":"crossref","unstructured":"Pickering LK. Antimicrobial resistance among enteric pathogens. Semin Pediatr Infect Dis.\u20082004;15:71\u201377","DOI":"10.1053\/j.spid.2004.01.009"},{"key":"2021120822583819900_R4","doi-asserted-by":"crossref","unstructured":"Carratala J, Fernandez-Sevilla A, Tubau F, Dominguez MA, Gudiol F. Emergence of fluoroquinolone-resistant Escherichia coli in fecal flora of cancer patients receiving norfloxacin prophylaxis. Antimicrob Agents Chemother.\u20081996;40:503\u2013505","DOI":"10.1128\/AAC.40.2.503"},{"key":"2021120822583819900_R5","doi-asserted-by":"crossref","unstructured":"McNeeley DF, Eckert SJ, Noel GJ. Antimicrobial-resistant enterococcal isolates from fluoroquinolone-naive children. Pediatr Infect Dis J.\u20082000;19:675\u2013676","DOI":"10.1097\/00006454-200007000-00029"},{"key":"2021120822583819900_R6","doi-asserted-by":"crossref","unstructured":"Sahm DF, Peterson DE, Critchley IA, Thornsberry C. Analysis of ciprofloxacin activity against Streptococcus pneumoniae after 10 years of use in the United States. Antimicrob Agents Chemother.\u20082000;44:2521\u20132524","DOI":"10.1128\/AAC.44.9.2521-2524.2000"},{"key":"2021120822583819900_R7","doi-asserted-by":"crossref","unstructured":"White RL, Enzweiler KA, Friedrich LV, Wagner D, Hoban D, Bosso JA. Comparative activity of gatifloxacin and other antibiotics against 4009 clinical isolates of Streptococcus pneumoniae in the United States during 1999\u20132000. Diagn Microbiol Infect Dis.\u20082002;43:207\u2013217","DOI":"10.1016\/S0732-8893(02)00391-7"},{"key":"2021120822583819900_R8","doi-asserted-by":"crossref","unstructured":"Chen DK, McGeer A, de Azavedo JC, Low DE. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. N Engl J Med.\u20081999;341:233\u2013239","DOI":"10.1056\/NEJM199907223410403"},{"key":"2021120822583819900_R9","doi-asserted-by":"crossref","unstructured":"Ho PL, Que TL, Tsang DN, Ng TK, Chow KH, Seto WH. Emergence of fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae in Hong Kong. Antimicrob Agents Chemother.\u20081999;43:1310\u20131313","DOI":"10.1128\/AAC.43.5.1310"},{"key":"2021120822583819900_R10","doi-asserted-by":"crossref","unstructured":"Ho PL, Tse WS, Tsang KW, et al. Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: a case-control study. Clin Infect Dis.\u20082001;32:701\u2013707","DOI":"10.1086\/319222"},{"key":"2021120822583819900_R11","doi-asserted-by":"crossref","unstructured":"Zervos MJ, Hershberger E, Nicolau DP, et al. Relationship between fluoroquinolone use and changes in susceptibility to fluoroquinolones of selected pathogens in 10 United States teaching hospitals, 1991\u20132000. Clin Infect Dis.\u20082003;37:1643\u20131648","DOI":"10.1086\/379709"},{"key":"2021120822583819900_R12","doi-asserted-by":"crossref","unstructured":"Mullen CA. Ciprofloxacin in treatment of fever and neutropenia in pediatric cancer patients. Pediatr Infect Dis J.\u20082003;22:1138\u20131142","DOI":"10.1097\/01.inf.0000101993.83884.ed"},{"key":"2021120822583819900_R13","doi-asserted-by":"crossref","unstructured":"Cao XT, Kneen R, Nguyen TA, Truong DL, White NJ, Parry CM. A comparative study of ofloxacin and cefixime for treatment of typhoid fever in children. The Dong Nai Pediatric Center Typhoid Study Group. Pediatr Infect Dis J.\u20081999;18:245\u2013248","DOI":"10.1097\/00006454-199903000-00007"},{"key":"2021120822583819900_R14","doi-asserted-by":"crossref","unstructured":"Zimbabwe, Bangladesh, South Africa (Zimbasa) Dysentery Study Group. Multicenter, randomized, double-blind clinical trial of short course versus standard course oral ciprofloxacin for Shigella dysenteriae type 1 dysentery in children. Pediatr Infect Dis J.\u20082002;21:1136\u20131141","DOI":"10.1097\/00006454-200212000-00010"},{"key":"2021120822583819900_R15","doi-asserted-by":"crossref","unstructured":"Leibovitz E, Janco J, Piglansky L, et al. Oral ciprofloxacin vs. intramuscular ceftriaxone as empiric treatment of acute invasive diarrhea in children. Pediatr Infect Dis J.\u20082000;19:1060\u20131067","DOI":"10.1097\/00006454-200011000-00006"},{"key":"2021120822583819900_R16","doi-asserted-by":"crossref","unstructured":"Safdar M, Said A, Gangnon RE, Maki DG. Risk of hematolytic uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 enteritis: a meta-analysis. JAMA.\u20082002;288:996\u20131001","DOI":"10.1001\/jama.288.8.996"},{"key":"2021120822583819900_R17","doi-asserted-by":"crossref","unstructured":"Johansson A, Berglund L, Gothefors L, Sjostedt A, Tarnvik A. Ciprofloxacin for treatment of tularemia in children. Pediatr Infect Dis J.\u20082000;19:449\u2013453","DOI":"10.1097\/00006454-200005000-00011"},{"key":"2021120822583819900_R18","doi-asserted-by":"crossref","unstructured":"Saez-Llorens X, McCoig C, Feris JM, et al. Quinolone treatment for pediatric bacterial meningitis: a comparative study of trovafloxacin and ceftriaxone with or without vancomycin. Pediatr Infect Dis J.\u20082002;21:14\u201322","DOI":"10.1097\/00006454-200201000-00004"},{"key":"2021120822583819900_R19","doi-asserted-by":"crossref","unstructured":"Leibovitz E, Piglansky L, Raiz S, et al. Bacteriologic and clinical efficacy of oral gatifloxacin for the treatment of recurrent\/nonresponsive acute otitis media: an open label, noncomparative, double tympanocentesis study. Pediatr Infect Dis J.\u20082003;22:943\u2013949","DOI":"10.1097\/01.inf.0000095468.89866.14"},{"key":"2021120822583819900_R20","doi-asserted-by":"crossref","unstructured":"Arguedas A, Sher L, Lopez E, et al. Open label, multicenter study of gatifloxacin treatment of recurrent otitis media and acute otitis media treatment failure. Pediatr Infect Dis J.\u20082003;22:949\u2013956","DOI":"10.1097\/01.inf.0000095193.42502.d1"},{"key":"2021120822583819900_R21","unstructured":"Cipro (ciprofloxacin hydrochloride) [package insert]. West Haven, CT: Bayer Pharmaceutical Corporation; 2004. Available at: www.fda.gov\/cder\/foi\/label\/2004\/19537s049,19857s031,19847se5-027,20780se5-013_cipro_lbl.pdf. Accessed February 3, 2005"},{"key":"2021120822583819900_R22","doi-asserted-by":"crossref","unstructured":"Grady R. Safety profile of quinolone antibiotics in the pediatric population. Pediatr Infect Dis J.\u20082003;22:1128\u20131132","DOI":"10.1097\/01.inf.0000101994.25947.12"},{"key":"2021120822583819900_R23","doi-asserted-by":"crossref","unstructured":"Burstein GR, Berman SM, Blumer JL, Moran JS. Ciprofloxacin for the treatment of uncomplicated gonorrhea infection in adolescents: does the benefit outweigh the risk?Clin Infect Dis.\u20082002;35(suppl 2):S191\u2013S199","DOI":"10.1086\/342107"},{"key":"2021120822583819900_R24","doi-asserted-by":"crossref","unstructured":"Yee CL, Duffy C, Gerbino PG, Stryker S, Noel GJ. Tendon or joint disorders in children after treatment with fluoroquinolones or azithromycin. Pediatr Infect Dis J.\u20082002;21:525\u2013529","DOI":"10.1097\/00006454-200206000-00009"},{"key":"2021120822583819900_R25","doi-asserted-by":"crossref","unstructured":"Khaliq Y, Zhanel GG. Fluoroquinolone-associated tendinopathy: a critical review of the literature. Clin Infect Dis.\u20082003;36:1404\u20131410","DOI":"10.1086\/375078"},{"key":"2021120822583819900_R26","unstructured":"US Preventive Services Task Force. Appendix A: task force ratings. In: Guide to Clinical Preventive Services. 2nd ed. Rockville, MD: US Preventive Services Task Force, US Department of Health and Human Services; 1996:862"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/118\/3\/1287\/1073852\/zpe00906001287.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/118\/3\/1287\/1073852\/zpe00906001287.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T02:56:23Z","timestamp":1639018583000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/118\/3\/1287\/69414\/The-Use-of-Systemic-Fluoroquinolones"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,9,1]]},"references-count":26,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2006,9,1]]},"published-print":{"date-parts":[[2006,9,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2006-1722","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,9,1]]}}}